Patents Assigned to FRED
-
Patent number: 6745773Abstract: A tracheal tube by which the trachea is closed watertight by a fixation cuff blocking the trachea below the glottis, through which a ventilation cannula passes, and, situated cranially to it, above the cuff, a tampon-bladder made of flexible material expansible through the influx of fluid, which when filled differs in shape from the shape of the cuff, would represent an improvement by means of which a patient could be intubated in the gentlest way over a long period with minimal risk of infection. In the invention this is accomplished by situating the tampon-bladder immediately against the cuff and constructing it of foil-like material and so designing it that when fully distended in size it fills the subglottal space.Type: GrantFiled: June 3, 1999Date of Patent: June 8, 2004Assignee: Dr. Fred Goebel Patentverwaltung GmbHInventor: Fred G. Gobel
-
Publication number: 20040034878Abstract: Hypercellular nonhuman organisms have functionally inactivated expression of a cyclin inhibitor gene, especially p27. The growth rate of nonhuman organisms are increased such that a desired size is attained more quickly than as compared to nonvariant organisms. Inhibitors of the p27 cyclin dependent kinase inhibitor protein or sequences encoding the protein modulate vertebrate cell cycle progression and increase the proportion of dividing cells to non-dividing cells in a population of treated cells. As the proportion of dividing cells increases, the cell population, e.g., hematopoietic progenitor (stem) cells, is more efficiently used for gene therapy applications. Transgenic animals and plants, and knockout alleles are provided.Type: ApplicationFiled: April 3, 2003Publication date: February 19, 2004Applicant: Fred Hutchinson Cancer Research CenterInventors: James M. Roberts, Steven R. Coats, Matthew L. Fero
-
Publication number: 20030219797Abstract: A method for analyzing large data arrays is provided. In one aspect, the invention provides a method for analyzing data from two or more data arrays. Each array includes a plurality of members, each member provides a signal, and the data is indexed by one or more parameters. In one embodiment, the method includes fitting a model to the data; determining the goodness of the fit by evaluating the statistical significance of the fit; and determining the statistical significance of the signal. In another embodiment, the method further includes correcting the data for heterogeneity among members prior to fitting the model to the data.Type: ApplicationFiled: February 26, 2003Publication date: November 27, 2003Applicant: Fred Hutchinson Cancer Research CenterInventors: Lue Ping Zhao, Ross Prentice, Linda Breeden
-
Patent number: 6635450Abstract: An isolated protein designated p27 is disclosed. The p27 protein has an apparent molecular weight of about 27 kD, and is capable of binding to and inhibiting the activation of a cyclin E-Cdk2 complex. A nucleic acid sequence encoding p27 protein is disclosed, as well as a method for producing p27 in cultured cells. in vitro assays for discovering agents which effect the activity of p27 are also provided. Methods of diagnosing and treating hypoproliferative and hyperproliferative disorders are provided.Type: GrantFiled: April 28, 1997Date of Patent: October 21, 2003Assignees: Fred Hutchinson Institute for Cancer Research, Sloan-Kettering Institute for Cancer ResearchInventors: Joan Massague, James M. Roberts, Andrew Koff, Kornelia Polyak
-
Publication number: 20030165835Abstract: The present invention provides various methods by which the use of certain MHC-related molecules can be exploited in understanding and regulating the immune response. More particularly, the present invention describes the use of molecules expressed by certain cell types as markers, reagents and targets in the diagnosis and treatment of certain disease states including GVHD, cancer and the like.Type: ApplicationFiled: May 14, 2001Publication date: September 4, 2003Applicant: Fred Hutchinson Cancer Research Center Inc.Inventors: Thomas Spies, Veronika Spies
-
Patent number: 6596501Abstract: The present invention relates to diagnostic applications. For autoimmune diseases more particularly, it is demonstrated herein that individuals with SLE, APLA, MCDS and PSS have antibodies that are specific for SR proteins. Thus, in particular aspects the present invention provides methods and compositions for diagnosing autoimmune disease using SR proteins and antibodies to detect the presence of SR protein-specific antibodies in an individual suspected of having autoimmune disease, wherein the presence of such antibodies is indicative of said individual suffering from autoimmune disease.Type: GrantFiled: February 23, 1999Date of Patent: July 22, 2003Assignee: Fred Hutchinson Cancer Research CenterInventor: Mark Roth
-
Publication number: 20030104357Abstract: The present invention demonstrates that JSRV envelope protein (Env) can be used to transduce human and other mammalian cells. Hybrid retrovirus packaging cells have been constructed that express the JSRV Env and retrovirus Gag-Pol proteins, and can produce JSRV-pseudotype vectors at high titers. Using high-titer virus the host range for JSRV has been established, and included sheep, human, monkey, bovine and dog cells, but not murine, rat or hamster cells. Retroviral packaging cell lines comprising the JSRV envelope protein, and receptor binding fragments thereof, are provided which transiently and stably produce high titers of recombinant retrovirus particles which can be used to transfer a heterologous gene to a eukaryotic cell.Type: ApplicationFiled: March 29, 2002Publication date: June 5, 2003Applicant: Fred Hutchinson Cancer Research CenterInventors: Sharath K. Rai, Arthur Dusty Miller
-
Publication number: 20020197717Abstract: Immortalized human stromal cell lines sustain and expand human hematopoietic precursor cells. The precursor cells are obtained from a blood product and inoculated into a culture medium conditioned by exposure to a human stromal cell line. Preferred human stromal cell lines secrete SCF, LIF, MIP1&agr;, and IL-6, as exemplified by a human stromal cell line designated HS-1. The conditioned culture medium may be supplemented with additional growth factors, such as interleukin-3. After expansion the human hematopoietic precursor cells are harvested and returned to a patient or frozen and stored. The immortalized human stromal cell lines can also be used as feeder layers in ex vivo bone marrow cultures or in colony forming assays.Type: ApplicationFiled: June 4, 2002Publication date: December 26, 2002Applicant: Fred Hutchinson Cancer Research CenterInventors: Beverly Torok-Storb, Bryan A. Roecklein, Gretchen Johnson
-
Patent number: 6461864Abstract: Transgenic non-human animals one having a general deletor construct and a second having a general reporter construct are described. The general deletor animals express a heterologous recombinase under the control of an ubiquitously expressed endogenous promoter. Specifically, the Cre recombinase is inserted into the ROSA26 locus of the mouse. The general reporter animals have a gene which is desired to remove flanked by sites recognized by the is heterologous recombinase. This flanked sequence is operatively associated with a marker gene such that when the gene sequence flanked by sites recognized by the heterologous recombinase is excised, the reporter gene is expressed. When the general deletor mouse is crossed with the general reporter mouse the heterologous recombinase is expressed in essentially all cells of the resultant descendants under the control of the ubiquitous promoter. Expression of the recombinase results in the excision of the desired gene in essentially all cells of the descendant animals.Type: GrantFiled: April 14, 1999Date of Patent: October 8, 2002Assignee: Fred Hutchinson Cancer Research CenterInventors: Philippe Soriano, Elizabeth J. Robertson
-
Patent number: 6461807Abstract: The present invention provides methods for identifying targets of a drug in a cell by comparing (i) the effects of the drug on a wild-type cell, (ii) the effects on a wild-type cell of modifications to a putative target of the drug, and (iii) the effects of the drug on a wild-type cell which has had the putative target modified of the drug. In various embodiments, the effects on the cell can be determined by measuring gene expression, protein abundances, protein activities, or a combination of such measurements. In various embodiments, modifications to a putative target in the cell can be made by modifications to the genes encoding the target, modification to abundances of RNAs encoding the target, modifications to abundances of target proteins, or modifications to activities of the target proteins. The present invention also provides methods for drug development based on the methods for identifying drug targets.Type: GrantFiled: November 10, 2000Date of Patent: October 8, 2002Assignee: Fred Hutchinson Cancer Research CenterInventors: Stephen H. Friend, Leland Hartwell
-
Patent number: 6444463Abstract: Provided are methods of classifying and prognosticating human neuroectodermal tumors by analyzing a sample of the tumor to determine whether various bHLH proteins are detectably expressed in the sample. In the methods disclosed herein, expression of the bHLH genes is assessed by measuring transcripts or proteins expressed from the genes.Type: GrantFiled: February 7, 2000Date of Patent: September 3, 2002Assignee: Fred Hutchinson Cancer Research CenterInventor: Stephen J. Tapscott
-
Patent number: 6420374Abstract: A family of compounds effective in suppressing lymphocyte activation is comprised of 7-(oxoalkyl)1,3-dialkyl xanthines, other than denbufylline, of the formula in which R1 and R2 are the same or different and are selected from the group consisting of straight-chain or branched alkyl radicals with 2 to 6 carbon atoms, cyclohexyl, alkoxyalkyl and hydroxyalkyl radicals, and A represents a hydrocarbon radical with up to 4 carbon atoms which can be substituted by a methyl group.Type: GrantFiled: November 6, 1996Date of Patent: July 16, 2002Assignee: Fred Hutchinson Cancer Research CenterInventors: James A. Bianco, Jack W. Singer, William J. Novick, Jr.
-
Immunologically significant herpes simplex virus antigens and methods for identifying and using same
Patent number: 6413518Abstract: The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are epitopes confirmed to be recognized by T-cells derived from herpetic lesions. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.Type: GrantFiled: September 28, 2000Date of Patent: July 2, 2002Assignees: University of Washington, Fred Hutchinson Cancer Research Center, Corixa CorporationInventors: David M. Koelle, Hongbo Chen, Lawrence Corey, Nancy Ann Hosken, Patrick McGowan, Steven P. Fling, Christine M. Posavad -
Publication number: 20020064784Abstract: The present invention relates to a method of identifying one or more secondary drug targets and their use in the identification of drug or drug candidates, particularly for the treatment of cancer. The yeast-based synthetic lethal screens were used to functionally identify and validate new gene targets to kill tumor cells with defects in cell cycle checkpoints and damage response pathways. These newly identified gene targets can be used to develop new cancer chemotherapeutics.Type: ApplicationFiled: May 3, 2001Publication date: May 30, 2002Applicant: Fred Hutchinson Cancer Research CenterInventors: Stephen Friend, Leland Hartwell
-
Patent number: 6368862Abstract: rDNA promoter constructs useful in plasmids and vectors directing transcription of RNAs in a Pol I-specific manner constructed of four elements in a serial array: a first nucleotide sequence, capable of hybridizing under stringent conditions to an rDNA promoter element; a second nucleotide sequence, capable of hybridizing under stringent conditions to an internal ribosome entry signal (IRES); a third nucleotide sequence containing a coding region interest; a fourth nucleotide sequence containing a polyadenylation (polyA) signal sequence; a fifth rDNA enhancer element may be positioned upstream of the serial array. Also recombinant permissive cells and genetically engineered stable cell lines that contain the subject constructs.Type: GrantFiled: March 4, 1992Date of Patent: April 9, 2002Assignee: Fred Hutchinson Cancer Research CenterInventors: Theodore D. Palmer, Brian M. McStay, A. Dusty Miller, Ronald H. Reeder
-
Patent number: 6355774Abstract: An isolated protein designated p27 is disclosed. The p27 protein has an apparent molecular weight of about 27 kD, and is capable of binding to and inhibiting the activation of a cyclin E-Cdk2 complex. A nucleic acid sequence encoding p27 protein is disclosed, as well as a method for producing p27 in cultured cells. In vitro assays for discovering agents which affect the activity of p27 are also provided. Methods of diagnosing and treating hypoproliferative disorders are provided.Type: GrantFiled: May 9, 1997Date of Patent: March 12, 2002Assignees: Fred Hutchinson Cancer Research Center, Kettering Institute for Cancer ResearchInventors: Joan Massague, James M. Roberts, Andrew Koff, Kornelia Polyak
-
Patent number: 6319707Abstract: Retroviral vectors for producing coordinately expressed polycistronic mRNA in transfected host cells. A representative retroviral construct capable of forming a proviral genome in a host cell contains a first nucleotide coding sequence, a second nucleotide coding sequence, and a third nucleotide sequence capable of hybridizing under stringent conditions to a 5′ nontranslated region (NTR) of a picornavirus RNA or its complementary RNA strand. The first, second, and third nucleotide sequences are operably linked such that transcription of the proviral genome gives rise to a messenger RNA molecule containing transcripts of the first, second, and third nucleotide sequences. The transcript of the third nucleotide sequence in the messenger RNA molecule contains a nucleic acid capable of forming a regulatory stem-loop nucleic acid structure followed by at least one operable AUG start codon.Type: GrantFiled: January 26, 1993Date of Patent: November 20, 2001Assignee: Fred Hutchinson Cancer Research Center Board Regents of the University of WashingtonInventors: Mohammed A. Adam, A. Dusty Miller, William Reginald Alfred Osborne
-
Patent number: 6316208Abstract: The subject invention is directed to the discovery of a protein involved in regulation of cell-cycle progression, and includes reagents and methods related thereto.Type: GrantFiled: February 3, 1997Date of Patent: November 13, 2001Assignees: Memorial Sloan-Kettering Cancer Center, Fred Hutchinson Cancer Research CenterInventors: James M. Roberts, Peggy L. Porter, Kornelia Polyak, Joan Massague, Andrew Koff
-
Patent number: 6242575Abstract: The subject invention provides an isolated protein having an apparent molecular weight of about 27 kD and capable of binding to and inhibiting the activation of a cyclin E-Cdk2 complex. The subject invention further provides an isolated antibody and a purified preparation of polyclonal and monoclonal antibodies which are specifically immunoreactive with a p27 protein. The subject invention further provides a kit for detecting a p27 protein.Type: GrantFiled: February 21, 1997Date of Patent: June 5, 2001Assignees: Fred Hutchinson Institute for Cancer Research, Sloan-Kettering Institute for Cancer ResearchInventors: Joan Massague, James M. Roberts, Andrew Koff, Kornelia Polyak
-
Patent number: 6204364Abstract: Hybrid cytokines containing four helical regions, each of which is derived from a corresponding &agr;-helical region in leukemia inhibitory factor (LIF), granulocyte colony stimulating factor (G-CSF), interleukin-6 (IL-6) or oncostatin-M (OSM) are disclosed. These hybrid cytokines may further contain linking regions also derived from corresponding linking regions in these factors. The hybrid cytokines offer a unique spectrum of activities useful in treating conditions for which the native cytokines are useful or in treating conditions characterized by an excess of the native cytokines.Type: GrantFiled: July 27, 1993Date of Patent: March 20, 2001Assignee: Fred Hutchinson Research CenterInventors: George J. Todaro, Timothy M. Rose